Search results for Car-T Therapy

B Cell-Targeted CAR-T Therapy Shapes Vaccine Immunity

In the rapidly evolving landscape of immunotherapy, CAR-T cell therapy has emerged as a beacon of hope for treating various malignancies, particularly hematologic cancers. A ground...

Chimeric antigen receptor T-cell therapy in neurological disorders: Emerging applications, evidence, and challenges

Chimeric antigen receptor (CAR) T-cell therapy, initially developed for hematologic malignancies, engineers autologous T cells to eliminate pathogenic immune populations and aims t...

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory dis...

Dual-Targeted CAR T Cells Beat Escape, Rejection

In a groundbreaking advancement poised to redefine the landscape of immunotherapy, researchers have unveiled a novel strategy employing allogeneic CD19 CAR T cells augmented with a...

CAR T therapy induces remission in multiple autoimmune diseases

For the first time, scientists have used a cutting-edge cell therapy called CAR-T to treat a patient with three different life-threatening autoimmune diseases that had resisted yea...

In Vivo CAR-Neutrophils Developed for Glioma Treatment

In a groundbreaking advancement poised to redefine cancer immunotherapy, researchers have surmounted one of the most formidable challenges in cell-based therapies: the direct genet...

CAR-T cell therapies going in vivo  

There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit the clinic. The post CAR-T cell therapies going in vivo  ...

Key CAR-T Cell Traits Trigger Myeloid Activation

In a groundbreaking study that could redefine the landscape of cellular immunotherapy, researchers have delved deep into the molecular and cellular dynamics underpinning CAR-T cell...

Cytokine‑Armored CAR T Cells Overcome Antigen Heterogeneity in Glioma Model

Scientists developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice, which they paired with a CAR T strategy targe...

CAR T-cell therapy takes woman from bedridden to 'perfectly fine'

A woman with three different autoimmune conditions had all of them treated simultaneously by genetically modifying her immune cells to kill off the rogue ones causing problems

Bloodlines Series: CAR T-cell Therapy Shows Promise for Smoldering Myeloma

An immunotherapy typically used in advanced stages of multiple myeloma may be effective against an early form of the disease known as smoldering myeloma—offering a potential new op...

CAR T Cell Therapy Biomanufactured by Cellares Infused Into First Two Patients

The scalable biomanufacturing of autologous products to supply thousands of patients per year can potentially be achieved with minimal capital investment and a low cost of goods. T...

Rewriting CAR T From Within

In vivo engineering strategies promise faster, scalable cell therapies and a streamlined path from discovery to clinical development. The post Rewriting CAR T From Within appeared...

CAR T-cell therapy bolstered by stiffening up cancer cells first

CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand could make it even more effective

Breakthrough in CAR T Cell Therapy: Insights from Successfully Treated AML Patients

A groundbreaking advance in the treatment of acute myeloid leukemia (AML) heralds a new era in immunotherapy, addressing a long-standing challenge of targeting cancer cells without...

Scientists Discover Genetic “Off Switch” That Supercharges CAR T Cells Against Cancer

A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single gene-regulating protein. CAR T-cell therapy is widely seen as a break...

Novel KIR‑CAR T Approach Shows Early Activity Against Solid Tumors

Early results presented at AACR show that a novel KIR‑CAR T therapy demonstrates safety and efficacy in solid tumors, pointing to a new strategy for addressing T cell exhaustion an...

In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient

A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, providing further proof of the modality’s promise in t...

CAR-T therapy for stiff person syndrome nears approval

No medicines have been approved for stiff person syndrome yet. However, Kyverna Therapeutics' CAR-T cell therapy is headed towards approval. The post CAR-T therapy for stiff perso...

Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy. 

From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma

SHANGHAI, May 24, 2026 /PRNewswire/ -- A 36-year-old Pakistani patient has achieved encouraging early recovery after receiving personalized CAR-T immunotherapy at Jiahui Internatio...

Allogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of data

Cema-cel eradicated minimal residual disease in seven of 12 patients, compared to two of 12 participants in the observational control arm.

Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both

It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therapies.

Learning from CAR T-Cell Therapy in Pediatric Autoimmunity: Potential Applications for Gastroenterology